- Trials with a EudraCT protocol (52)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
52 result(s) found for: Cell Communication.
Displaying page 1 of 3.
EudraCT Number: 2020-005332-30 | Sponsor Protocol Number: ACT16845 | Start Date*: 2021-09-27 | ||||||||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT | ||||||||||||||||||
Full Title: A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR- 707) combined with cemiplimab for the treatment of participants with adva... | ||||||||||||||||||
Medical condition: Advanced unresectable or metastatic skin cancers | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003760-30 | Sponsor Protocol Number: EMR63325-021 | Start Date*: 2014-04-30 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-smal... | |||||||||||||
Medical condition: unresectable stage III non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) AT (Completed) BE (Completed) DE (Prematurely Ended) SE (Completed) PT (Completed) IT (Completed) IE (Completed) SK (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000445-79 | Sponsor Protocol Number: EMR100070-003 | Start Date*: 2014-10-20 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel cell carcinoma | |||||||||||||
Medical condition: Merkel Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) DE (Completed) AT (Ongoing) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004040-28 | Sponsor Protocol Number: MS200647_0024 | Start Date*: 2019-04-11 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non-small Cell Lung Cancer | |||||||||||||
Medical condition: Stage IV Non-small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001517-32 | Sponsor Protocol Number: MS200647-0037 | Start Date*: 2019-11-28 | |||||||||||
Sponsor Name:Merck Healthcare KGaA | |||||||||||||
Full Title: An Adaptive Phase III Multicenter, Randomized, Open- Label, Controlled Study of M7824 (bitrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-... | |||||||||||||
Medical condition: Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) GR (Restarted) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003265-34 | Sponsor Protocol Number: MS200647_0005 | Start Date*: 2019-06-04 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participa... | |||||||||||||
Medical condition: Unresectable Stage III Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Completed) BE (Completed) NL (Completed) ES (Prematurely Ended) HU (Prematurely Ended) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004148-35 | Sponsor Protocol Number: EMR 200037-014 | Start Date*: 2010-04-19 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: Cilengitide and cetuximab in combination with platinum-based chemotherapy as first-line treatment for subjects with advanced NSCLC. Open-label, randomized, controlled, multicenter Phase II study in... | |||||||||||||
Medical condition: Advanced non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001144-18 | Sponsor Protocol Number: MS202359_0002 | Start Date*: 2022-09-29 | |||||||||||
Sponsor Name:MERCK HEALTHCARE KGaA | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement... | |||||||||||||
Medical condition: Resected squamous cell carcinoma of the head and neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) PT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004231-25 | Sponsor Protocol Number: MS201923_0050 | Start Date*: 2021-05-11 | |||||||||||
Sponsor Name:MERCK HEALTHCARE KGaA | |||||||||||||
Full Title: A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinumresistant small-cell lung cancer | |||||||||||||
Medical condition: Relapsed platinum resistant small-cell lung cancer (SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001529-24 | Sponsor Protocol Number: MS201944-0170 | Start Date*: 2018-08-31 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase IIa, single-arm, multi center study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with advanced sq... | |||||||||||||
Medical condition: Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000615-15 | Sponsor Protocol Number: EMR200052-013 | Start Date*: 2008-07-14 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: Open-label, randomized, controlled Phase I/II study of cilengitide to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin, 5-FU, and cetuxima... | |||||||||||||
Medical condition: Recurrent/metastatic squamous cell cancer of the head and neck. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) DE (Completed) FR (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002053-30 | Sponsor Protocol Number: EMR200095-005 | Start Date*: 2014-05-16 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liv... | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000605-72 | Sponsor Protocol Number: CB+MSCforEB | Start Date*: 2014-02-06 |
Sponsor Name:Universitair Medisch Centrum Utrecht | ||
Full Title: Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa | ||
Medical condition: The source population consists of patients referred to or within the UMC Groningen because they have diagnosed clinically and genetically severe generalized RDEB. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000714-37 | Sponsor Protocol Number: MK-3475-799 | Start Date*: 2018-11-05 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Canc... | |||||||||||||
Medical condition: Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003032-39 | Sponsor Protocol Number: CLEE011X2110C | Start Date*: 2014-12-26 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive Non-small Cell Lung Cancer | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001604-28 | Sponsor Protocol Number: EMR200095-006 | Start Date*: 2017-02-07 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib(MSC2156119J) Combined with Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects with MET Positive, Locally... | |||||||||||||
Medical condition: Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) SK (Ongoing) BG (Completed) NL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002985-28 | Sponsor Protocol Number: MS100070-0306 | Start Date*: 2018-03-02 | ||||||||||||||||
Sponsor Name:Merck KGaA | ||||||||||||||||||
Full Title: Open-label, Phase I/II study to evaluate pharmacokinetics, pharmacodynamics, safety, and anticancer activity of avelumab in pediatric subjects from birth to less than 18 years of age with refractor... | ||||||||||||||||||
Medical condition: Solid tumors (including central nervous system tumors) and lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014440-10 | Sponsor Protocol Number: EMR200068-006 | Start Date*: 2009-12-03 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naïve Subjects with Recurrent or Metastatic Squ... | |||||||||||||
Medical condition: Recurrent/metastatic squamous cell cancer of the head and neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) FR (Completed) SK (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002430-36 | Sponsor Protocol Number: AntibioTICS | Start Date*: 2012-07-02 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: Multicentre, randomised, double-blinded, placebo-controlled trial of efficacy of amoxicilline/clavulanic acid in patients affected by tic disorder colonized by GAS. No-proft stidy. | |||||||||||||
Medical condition: Chronic tic disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001254-29 | Sponsor Protocol Number: I2R-MC-BIAM | Start Date*: 2012-01-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Protocol I2R-MC-BIAM The Impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, R... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Completed) LT (Completed) GR (Completed) IT (Completed) DK (Completed) NL (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.